Medilink Therapeutics (suzhou) Co., Ltd.
Clinical trials sponsored by Medilink Therapeutics (suzhou) Co., Ltd., explained in plain language.
-
New hope for esophageal cancer: experimental drug YL201 faces chemo in major trial
Disease control Not yet recruitingThis large study tests whether a new medicine called YL201 works better than standard chemotherapy for people with advanced esophageal cancer that has stopped responding to initial treatment. About 440 participants will be randomly assigned to receive either YL201 or a doctor-cho…
Phase: PHASE3 • Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd. • Aim: Disease control
Last updated May 14, 2026 12:02 UTC
-
New hope for lung cancer patients: experimental drug YL202 faces off against chemotherapy
Disease control Not yet recruitingThis study compares a new drug called YL202 to the standard chemotherapy docetaxel in people with advanced non-small cell lung cancer that has a specific EGFR mutation. Participants must have already tried an EGFR-targeted pill and platinum chemotherapy without success. The goal …
Phase: PHASE3 • Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd. • Aim: Disease control
Last updated May 13, 2026 15:59 UTC
-
New hope for advanced breast cancer: YL202 faces off against standard chemo in major trial
Disease control Not yet recruitingThis phase 3 study tests a new drug called YL202 against standard chemotherapy options in people with a common type of advanced breast cancer (HR+/HER2-) that has not responded to at least one prior chemotherapy. The main goal is to see if YL202 can delay cancer growth or improve…
Phase: PHASE3 • Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd. • Aim: Disease control
Last updated May 07, 2026 18:39 UTC